Pulmatrix, Inc.
Robert Connelly, CEO, Lexington, MA
Pulmatrix is discovering a new class of host-targeted therapies that treat, prevent and help control a broad range of respiratory infections and progressive respiratory diseases. Pulmatrix’s innovative pathogen independent approach harnesses the airway and lungs own natural biophysical and host defense mechanisms, offering potential for individual therapies that treat serious respiratory diseases including influenza, rhinovirus, COPD, asthma and cystic fibrosis.
Dr. Lauren Silverman (Board Seat)